Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
货号（Catalog No.）
CSD00259
通用名INN
Brodalumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
别名(Alternative names)
AMG827,KHK4827
靶点;物种(Specificity target name;species)
IL17RA/CD217[Homo sapiens]
种类(Species)
Homo sapiens
受体鉴定(Receptor identification)
IgG2-kappa
化学信息
CAS
1174395-19-7
存储条件(Storage)
store at -80°C

Note
For research use only. Not suitable for clinical or therapeutic use.